Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Current approaches to the management of brain metastases.

Suh JH, Kotecha R, Chao ST, Ahluwalia MS, Sahgal A, Chang EL.

Nat Rev Clin Oncol. 2020 Feb 20. doi: 10.1038/s41571-019-0320-3. [Epub ahead of print] Review.

PMID:
32080373
2.

Radiogenomic-Based Survival Risk Stratification of Tumor Habitat on Gd-T1w MRI Is Associated with Biological Processes in Glioblastoma.

Beig N, Bera K, Prasanna P, Antunes J, Correa R, Singh S, Saeed Bamashmos A, Ismail M, Braman N, Verma R, Hill VB, Statsevych V, Ahluwalia MS, Varadan V, Madabhushi A, Tiwari P.

Clin Cancer Res. 2020 Feb 20. doi: 10.1158/1078-0432.CCR-19-2556. [Epub ahead of print]

PMID:
32079590
3.

The role of immunotherapy in the management of patients with renal cell carcinoma and brain metastases.

Fallah J, Ahluwalia MS.

Ann Transl Med. 2019 Dec;7(Suppl 8):S313. doi: 10.21037/atm.2019.10.31. No abstract available.

4.

ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases.

Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders CK, Carrillo JA, Chalasani P, Kabos P, Puhalla SL, Tkaczuk KHR, Garcia A, Ahluwalia MS, Wefel JS, Lakhani N, Ibrahim NK.

Clin Cancer Res. 2020 Jan 22. pii: clincanres.3258.2019. doi: 10.1158/1078-0432.CCR-19-3258. [Epub ahead of print]

5.

Epstein-Barr virus-associated primary central nervous system lymphoma in a patient with diffuse cutaneous systemic sclerosis on long-term mycophenolate mofetil.

Chatterjee S, Angelov L, Ahluwalia MS, Yeaney GA.

Joint Bone Spine. 2020 Mar;87(2):163-166. doi: 10.1016/j.jbspin.2019.10.005. Epub 2019 Oct 24.

PMID:
31669807
6.

Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.

Balasubramanian SK, Sharma M, Venur VA, Schmitt P, Kotecha R, Chao ST, Suh JH, Angelov L, Mohammadi AM, Vogelbaum MA, Barnett GH, Jia X, Pennell NA, Ahluwalia MS.

Neuro Oncol. 2020 Feb 20;22(2):267-277. doi: 10.1093/neuonc/noz155.

PMID:
31648302
7.

Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells.

Peereboom DM, Alban TJ, Grabowski MM, Alvarado AG, Otvos B, Bayik D, Roversi G, McGraw M, Huang P, Mohammadi AM, Kornblum HI, Radivoyevitch T, Ahluwalia MS, Vogelbaum MA, Lathia JD.

JCI Insight. 2019 Nov 14;4(22). pii: 130748. doi: 10.1172/jci.insight.130748.

8.

Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma.

Tom MC, Park DYJ, Yang K, Leyrer CM, Wei W, Jia X, Varra V, Yu JS, Chao ST, Balagamwala EH, Suh JH, Vogelbaum MA, Barnett GH, Prayson RA, Stevens GHJ, Peereboom DM, Ahluwalia MS, Murphy ES.

Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1106-1112. doi: 10.1016/j.ijrobp.2019.08.025. Epub 2019 Aug 25.

PMID:
31461674
9.

Phase II study of Dovitinib in recurrent glioblastoma.

Sharma M, Schilero C, Peereboom DM, Hobbs BP, Elson P, Stevens GHJ, McCrae K, Nixon AB, Ahluwalia MS.

J Neurooncol. 2019 Sep;144(2):359-368. doi: 10.1007/s11060-019-03236-6. Epub 2019 Jul 11.

PMID:
31292802
10.

Letter: When Less is More: Dexamethasone Dosing for Brain Tumors.

Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen PY.

Neurosurgery. 2019 Sep 1;85(3):E607-E608. doi: 10.1093/neuros/nyz186. No abstract available.

PMID:
31215634
11.

Targeted Therapies for Brain Metastases.

Niranjan A, Lunsford LD, Ahluwalia MS.

Prog Neurol Surg. 2019;34:125-137. doi: 10.1159/000493057. Epub 2019 May 16. Review.

PMID:
31096209
12.

Risk Factors for Progression Among Low-Grade Gliomas After Gross Total Resection and Initial Observation in the Molecular Era.

Tom MC, Varra V, Leyrer CM, Park DY, Chao ST, Yu JS, Suh JH, Reddy CA, Balagamwala EH, Broughman JR, Kotagal KA, Vogelbaum MA, Barnett GH, Ahluwalia MS, Peereboom DM, Prayson RA, Stevens GHJ, Murphy ES.

Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1099-1105. doi: 10.1016/j.ijrobp.2019.04.010. Epub 2019 Apr 22.

PMID:
31022510
13.

The Impact of Sequencing PD-1/PD-L1 Inhibitors and Stereotactic Radiosurgery for Patients with Brain Metastasis.

Kotecha R, Kim JM, Miller JA, Juloori A, Chao ST, Murphy ES, Peereboom DM, Mohammadi AM, Barnett GH, Vogelbaum MA, Angelov L, Suh JH, Ahluwalia MS.

Neuro Oncol. 2019 Feb 23. pii: noz046. doi: 10.1093/neuonc/noz046. [Epub ahead of print]

PMID:
30796838
14.

Current Treatment Options for Breast Cancer Brain Metastases.

Raghunath A, Desai K, Ahluwalia MS.

Curr Treat Options Oncol. 2019 Feb 15;20(3):19. doi: 10.1007/s11864-019-0618-5. Review.

PMID:
30771009
15.

Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.

Parsai S, Miller JA, Juloori A, Chao ST, Kotecha R, Mohammadi AM, Ahluwalia MS, Murphy ES, Barnett GH, Vogelbaum MA, Angelov L, Peereboom DM, Suh JH.

J Neurosurg. 2019 Feb 8;132(2):503-511. doi: 10.3171/2018.10.JNS182340.

PMID:
30738402
16.

Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis.

Kim JM, Miller JA, Kotecha R, Chao ST, Ahluwalia MS, Peereboom DM, Mohammadi AM, Barnett GH, Murphy ES, Vogelbaum MA, Angelov L, Abraham J, Moore H, Budd GT, Suh JH.

Neuro Oncol. 2019 May 6;21(5):659-668. doi: 10.1093/neuonc/noz006.

PMID:
30726965
17.

Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases.

Juloori A, Miller JA, Parsai S, Kotecha R, Ahluwalia MS, Mohammadi AM, Murphy ES, Suh JH, Barnett GH, Yu JS, Vogelbaum MA, Rini B, Garcia J, Stevens GH, Angelov L, Chao ST.

J Neurosurg. 2019 Jan 18:1-9. doi: 10.3171/2018.8.JNS182100. [Epub ahead of print]

PMID:
30660120
18.

Brain metastases.

Achrol AS, Rennert RC, Anders C, Soffietti R, Ahluwalia MS, Nayak L, Peters S, Arvold ND, Harsh GR, Steeg PS, Chang SD.

Nat Rev Dis Primers. 2019 Jan 17;5(1):5. doi: 10.1038/s41572-018-0055-y. Review.

PMID:
30655533
19.

Upfront Magnetic Resonance Imaging-Guided Stereotactic Laser-Ablation in Newly Diagnosed Glioblastoma: A Multicenter Review of Survival Outcomes Compared to a Matched Cohort of Biopsy-Only Patients.

Mohammadi AM, Sharma M, Beaumont TL, Juarez KO, Kemeny H, Dechant C, Seas A, Sarmey N, Lee BS, Jia X, Fecci PE, Baehring J, Moliterno J, Chiang VL, Ahluwalia MS, Kim AH, Barnett GH, Leuthardt EC.

Neurosurgery. 2019 Dec 1;85(6):762-772. doi: 10.1093/neuros/nyy449.

PMID:
30476325
20.

Recent advances in managing brain metastasis.

Kotecha R, Gondi V, Ahluwalia MS, Brastianos PK, Mehta MP.

F1000Res. 2018 Nov 9;7. pii: F1000 Faculty Rev-1772. doi: 10.12688/f1000research.15903.1. eCollection 2018. Review.

21.

Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis.

Alban TJ, Alvarado AG, Sorensen MD, Bayik D, Volovetz J, Serbinowski E, Mulkearns-Hubert EE, Sinyuk M, Hale JS, Onzi GR, McGraw M, Huang P, Grabowski MM, Wathen CA, Ahluwalia MS, Radivoyevitch T, Kornblum HI, Kristensen BW, Vogelbaum MA, Lathia JD.

JCI Insight. 2018 Nov 2;3(21). pii: 122264. doi: 10.1172/jci.insight.122264.

22.

Novel Systemic Treatments for Brain Metastases From Lung Cancer.

Thapa B, Lauko A, Desai K, Venur VA, Ahluwalia MS.

Curr Treat Options Neurol. 2018 Sep 27;20(11):48. doi: 10.1007/s11940-018-0533-2. Review.

PMID:
30259236
23.

Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.

Blakeley JO, Grossman SA, Chi AS, Mikkelsen T, Rosenfeld MR, Ahluwalia MS, Nabors LB, Eichler A, Ribas IG, Desideri S, Ye X; Adult Brain Tumor Consortium.

Clin Cancer Res. 2019 Jan 1;25(1):73-79. doi: 10.1158/1078-0432.CCR-18-0110. Epub 2018 Aug 21.

24.

Management of Brain Metastases in the New Era of Checkpoint Inhibition.

Lauko A, Thapa B, Venur VA, Ahluwalia MS.

Curr Neurol Neurosci Rep. 2018 Aug 18;18(10):70. doi: 10.1007/s11910-018-0877-8. Review.

PMID:
30121715
25.

Expression of LC3B and FIP200/Atg17 in brain metastases of breast cancer.

Hashemi-Sadraei N, Müller-Greven GM, Abdul-Karim FW, Ulasov I, Downs-Kelly E, Burgett ME, Lauko A, Qadan MA, Weil RJ, Ahluwalia MS, Du L, Prayson RA, Chao ST, Budd TG, Barnholtz-Sloan J, Nowacki AS, Keri RA, Gladson CL.

J Neurooncol. 2018 Nov;140(2):237-248. doi: 10.1007/s11060-018-2959-5. Epub 2018 Aug 9.

PMID:
30094720
26.

Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O6-Methylguanine DNA Methyltransferase Status in Patients with Glioblastoma.

Sharma M, Bellamkonda S, Mohapatra S, Meola A, Jia X, Mohammadi A, Angelov L, Barnett GH, Vogelbaum M, Ahluwalia MS.

World Neurosurg. 2018 Aug;116:e147-e161. doi: 10.1016/j.wneu.2018.04.134. Epub 2018 Apr 27.

PMID:
29709748
27.

First-in-human evaluation of the Cleveland Multiport Catheter for convection-enhanced delivery of topotecan in recurrent high-grade glioma: results of pilot trial 1.

Vogelbaum MA, Brewer C, Barnett GH, Mohammadi AM, Peereboom DM, Ahluwalia MS, Gao S.

J Neurosurg. 2018 Apr 1:1-10. doi: 10.3171/2017.10.JNS171845. [Epub ahead of print]

PMID:
29652233
28.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.

Ahluwalia MS, Becker K, Levy BP.

Oncologist. 2018 Oct;23(10):1199-1209. doi: 10.1634/theoncologist.2017-0572. Epub 2018 Apr 12. Review.

29.

The Evolving Landscape of Brain Metastasis.

Valiente M, Ahluwalia MS, Boire A, Brastianos PK, Goldberg SB, Lee EQ, Le Rhun E, Preusser M, Winkler F, Soffietti R.

Trends Cancer. 2018 Mar;4(3):176-196. doi: 10.1016/j.trecan.2018.01.003. Epub 2018 Feb 21. Review.

30.

Risk Factors for Malignant Transformation of Low-Grade Glioma.

Murphy ES, Leyrer CM, Parsons M, Suh JH, Chao ST, Yu JS, Kotecha R, Jia X, Peereboom DM, Prayson RA, Stevens GHJ, Barnett GH, Vogelbaum MA, Ahluwalia MS.

Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):965-971. doi: 10.1016/j.ijrobp.2017.12.258. Epub 2017 Dec 21.

PMID:
29485076
31.

Targeted therapy of brain metastases: latest evidence and clinical implications.

Di Lorenzo R, Ahluwalia MS.

Ther Adv Med Oncol. 2017 Dec;9(12):781-796. doi: 10.1177/1758834017736252. Epub 2017 Nov 15. Review.

32.

Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation.

Cagney DN, Martin AM, Catalano PJ, Reitman ZJ, Mezochow GA, Lee EQ, Wen PY, Weiss SE, Brown PD, Ahluwalia MS, Arvold ND, Tanguturi SK, Haas-Kogan DA, Alexander BM, Redig AJ, Aizer AA.

Radiother Oncol. 2018 Mar;126(3):511-518. doi: 10.1016/j.radonc.2018.01.005. Epub 2018 Feb 3.

PMID:
29398153
33.

Systemic therapy for brain metastases.

Venur VA, Karivedu V, Ahluwalia MS.

Handb Clin Neurol. 2018;149:137-153. doi: 10.1016/B978-0-12-811161-1.00011-6. Review.

PMID:
29307351
34.

Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Alexander BM, Brown PD, Ahluwalia MS, Aoyama H, Baumert BG, Chang SM, Gaspar LE, Kalkanis SN, Macdonald DR, Mehta MP, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Lee EQ, Wen PY; Response Assessment in Neuro-Oncology (RANO) group.

Lancet Oncol. 2018 Jan;19(1):e33-e42. doi: 10.1016/S1470-2045(17)30692-7. Review.

PMID:
29304360
35.

Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Camidge DR, Lee EQ, Lin NU, Margolin K, Ahluwalia MS, Bendszus M, Chang SM, Dancey J, de Vries EGE, Harris GJ, Hodi FS, Lassman AB, Macdonald DR, Peereboom DM, Schiff D, Soffietti R, van den Bent MJ, Wefel JS, Wen PY.

Lancet Oncol. 2018 Jan;19(1):e20-e32. doi: 10.1016/S1470-2045(17)30693-9. Review.

PMID:
29304358
36.

Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution?

Brown PD, Ahluwalia MS, Khan OH, Asher AL, Wefel JS, Gondi V.

J Clin Oncol. 2018 Feb 10;36(5):483-491. doi: 10.1200/JCO.2017.75.9589. Epub 2017 Dec 22. Review.

37.

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z.

JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. Erratum in: JAMA. 2018 May 1;319(17):1824.

38.

A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.

Chinnaiyan P, Won M, Wen PY, Rojiani AM, Werner-Wasik M, Shih HA, Ashby LS, Michael Yu HH, Stieber VW, Malone SC, Fiveash JB, Mohile NA, Ahluwalia MS, Wendland MM, Stella PJ, Kee AY, Mehta MP.

Neuro Oncol. 2018 Apr 9;20(5):666-673. doi: 10.1093/neuonc/nox209.

39.

Treatment of Glioblastoma in Older Adults.

Braun K, Ahluwalia MS.

Curr Oncol Rep. 2017 Oct 26;19(12):81. doi: 10.1007/s11912-017-0644-z. Review.

PMID:
29075865
40.

Changing Treatment Paradigms for Brain Metastases From Melanoma-Part 2: When and How to Use the New Systemic Agents.

Venur VA, Funchain P, Kotecha R, Chao ST, Ahluwalia MS.

Oncology (Williston Park). 2017 Sep 15;31(9):659-67. Review.

41.

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.

Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY; Alliance for Clinical Trials in Oncology and ABTC.

Neuro Oncol. 2018 Mar 27;20(4):546-556. doi: 10.1093/neuonc/nox161.

42.

Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.

Angelov L, Mohammadi AM, Bennett EE, Abbassy M, Elson P, Chao ST, Montgomery JS, Habboub G, Vogelbaum MA, Suh JH, Murphy ES, Ahluwalia MS, Nagel SJ, Barnett GH.

J Neurosurg. 2018 Aug;129(2):366-382. doi: 10.3171/2017.3.JNS162532. Epub 2017 Sep 22.

PMID:
28937324
43.

Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival.

Müller-Greven G, Carlin CR, Burgett ME, Ahluwalia MS, Lauko A, Nowacki AS, Herting CJ, Qadan MA, Bredel M, Toms SA, Lathia JD, Hambardzumyan D, Sarkaria JN, Hamerlik P, Gladson CL.

Clin Cancer Res. 2017 Nov 15;23(22):7059-7071. doi: 10.1158/1078-0432.CCR-17-0249. Epub 2017 Sep 14.

44.

Prediction of new brain metastases after radiosurgery: validation and analysis of performance of a multi-institutional nomogram.

Ayala-Peacock DN, Attia A, Braunstein SE, Ahluwalia MS, Hepel J, Chung C, Contessa J, McTyre E, Peiffer AM, Lucas JT Jr, Isom S, Pajewski NM, Kotecha R, Stavas MJ, Page BR, Kleinberg L, Shen C, Taylor RB, Onyeuku NE, Hyde AT, Gorovets D, Chao ST, Corso C, Ruiz J, Watabe K, Tatter SB, Zadeh G, Chiang VLS, Fiveash JB, Chan MD.

J Neurooncol. 2017 Nov;135(2):403-411. doi: 10.1007/s11060-017-2588-4. Epub 2017 Aug 21.

45.

Changing Treatment Paradigms for Brain Metastases From Melanoma-Part 1: Diagnosis, Prognosis, Symptom Control, and Local Treatment.

Venur VA, Funchain P, Kotecha R, Chao ST, Ahluwalia MS.

Oncology (Williston Park). 2017 Aug 15;31(8):602-6. Review.

46.

Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.

Kotecha R, Miller JA, Venur VA, Mohammadi AM, Chao ST, Suh JH, Barnett GH, Murphy ES, Funchain P, Yu JS, Vogelbaum MA, Angelov L, Ahluwalia MS.

J Neurosurg. 2018 Jul;129(1):50-59. doi: 10.3171/2017.1.JNS162797. Epub 2017 Aug 11.

PMID:
28799876
47.

Novel therapeutic agents in the management of brain metastases.

Venur VA, Ahluwalia MS.

Curr Opin Oncol. 2017 Sep;29(5):395-399. doi: 10.1097/CCO.0000000000000393. Review.

PMID:
28787285
48.

Intensity modulated radiation therapy with pulsed reduced dose rate as a reirradiation strategy for recurrent central nervous system tumors: An institutional series and literature review.

Murphy ES, Rogacki K, Godley A, Qi P, Reddy CA, Ahluwalia MS, Peereboom DM, Stevens GH, Yu JS, Kotecha R, Suh JH, Chao ST.

Pract Radiat Oncol. 2017 Nov - Dec;7(6):e391-e399. doi: 10.1016/j.prro.2017.04.003. Epub 2017 Apr 12.

PMID:
28666902
49.

The Prognostic Role of Tumor Volume in the Outcome of Patients with Single Brain Metastasis After Stereotactic Radiosurgery.

Bennett EE, Angelov L, Vogelbaum MA, Barnett GH, Chao ST, Murphy ES, Yu JS, Suh JH, Jia X, Stevens GHJ, Ahluwalia MS, Mohammadi AM.

World Neurosurg. 2017 Aug;104:229-238. doi: 10.1016/j.wneu.2017.04.156. Epub 2017 May 3.

PMID:
28478250
50.

The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies.

Kim JM, Miller JA, Kotecha R, Xiao R, Juloori A, Ward MC, Ahluwalia MS, Mohammadi AM, Peereboom DM, Murphy ES, Suh JH, Barnett GH, Vogelbaum MA, Angelov L, Stevens GH, Chao ST.

J Neurooncol. 2017 Jun;133(2):357-368. doi: 10.1007/s11060-017-2442-8. Epub 2017 Apr 22.

PMID:
28434110

Supplemental Content

Loading ...
Support Center